Trial Profile
Pilot multicenter open label study on treatment with Sofosbuvir/Ledipasvir FDC for patients with thalassemia major and HCV infection.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
- 01 Aug 2017 Results published in the Alimentary Pharmacology and Therapeutics
- 01 Aug 2017 Status changed from active, no longer recruiting to completed according to results published in the Alimentary Pharmacology and Therapeutics.